| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-07-08 |
| タイトル |
|
|
タイトル |
Adjunct Therapy with Ipragliflozin Exerts Limited Effects on Kidney Protection in Type 1 Diabetes: A Retrospective Study Conducted at 25 Centers in Japan (IPRA-CKD) |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
ipragliflozin |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
type 1 diabetes |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
SGLT2 inhibitor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
chronic kidney disease |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
renal outcome |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Nakamura, Yuta
Horie, Ichiro
Yano, Hiroshi
Nomoto, Hiroshi
Fukui, Tomoyasu
Yuyama, Yoshihiko
Kawamura, Tomoyuki
Ueda, Mariko
Yamamoto, Akane
Hirota, Yushi
Kusunoki, Yoshikim
Nishida, Kenro
Sekiguchi, Dan
Maeda, Yasutaka
Minami, Masae
Nagayama, Ayako
Iwata, Shimpei
Minagawa, Hitomi
Furukawa, Shinya
Miyake, Teruki
Ueno, Hiroaki
Chinen, Rei
Nakayama, Yoshiro
Masuzaki, Hiroaki
Miyachi, Yasutaka
Okada, Yosuke
Okamoto, Mitsuhiro
Ono, Kaoru
Tanaka, Ken-ichi
Kurozumi, Akira
Sakai, Takenori
Yamasaki, Hironori
Yasui, Jun-ichi
Ito, Ayako
Kawakami, Atsushi
Abiru, Norio
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background/Objectives: While sodium–glucose cotransporter 2 (SGLT2) inhibitors have demonstrated additional non-glycemic benefits for renal protection in individuals with type 2 diabetes, less evidence is available for those with type 1 diabetes (T1D). To determine whether the adjunctive use of the SGLT2 inhibitor ipragliflozin confers kidney protection in individuals with T1D, we retrospectively analyzed data from a real-world cohort examined at 25 centers in Japan. Methods: We enrolled 359 subjects aged 20–74 years with T1D (IPRA group: 159 ipragliflozin users; control [CTRL] group: 200 non-users). The primary outcome was changes in the estimated glomerular filtration rate (eGFR) from baseline to 24 months after the initiation of ipragliflozin. The secondary outcomes were all other changes, including the urinary albumin–creatinine ratio (UACR) and urinary protein–creatinine ratio (UPCR). Results: The IPRA group’s eGFR decline slopes were 0.79 mL/min/1.73 m2/year milder than the CTRL group’s after propensity score matching, but this difference was not significant. The subjects complicated by chronic kidney disease (CKD) defined as UACR ≥ 30 mg/g and/or UPCR ≥ 0.5 g/g and/or eGFR < 60 mL/min/1.73 m2 showed changes in UPCR (g/g) from baseline to 24 months that were significantly lower in the IPRA group (−0.27 ± 1.63) versus the CTRL group (0.18 ± 0.36) (p = 0.016). No significant increase in adverse events (including severe hypoglycemia and hospitalization due to ketosis/ketoacidosis or cardiovascular diseases) was observed in the IPRA group. Conclusions: Adjunctive treatment with ipragliflozin exerted potential renal benefits by decreasing proteinuria in T1D subjects with CKD. Further investigations are required to determine whether its additional benefits exceed the increased risk of ketoacidosis. |
|
言語 |
en |
| 書誌情報 |
en : Biomedicines
巻 13,
号 6,
p. art. no. 1287,
発行日 2025-05-23
|
| 出版者 |
|
|
出版者 |
MDPI |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
2227-9059 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.3390/biomedicines13061287 |
| 権利 |
|
|
権利情報 |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Biomedicines, 13(6), art. no. 1287; 2025 |
|
言語 |
en |
B13_1287.pdf (3.1 MB)
